Asociaciones entre el Riesgo Cardiovascular y las Tasas de Incidencia de Eventos Cardiovasculares Mayores y Malignidades en Pacientes con Artritis Psoriásica y Psoriasis Recibiendo Tofacitinib
Ther Adv Musculoskelet Dis. 2023 doi: 10.1177/1759720X221149965
Baseline 10-year atherosclerotic cardiovascular disease risk and metabolic syndrome are potentially associated with the incidence of both MACE and malignancies in patients receiving TOFA in the PsA and PsO clinical trial programs. This post hoc analysis aimed to examine the baseline CV disease risk and its association with the occurrence of MACE and malignancies in TOFA-treated patients with PsA and PsO.
These results confirm the importance of assessing CV risk and adequate prevention in patients with PsA and PsO and suggest enhanced cancer monitoring in patients with significant 10-year ASCVD risk.
Keywords:
